Henagliflozin

Henagliflozin
Clinical data
Trade namesRui Qin; 瑞沁
Other namesSHR3824; SHR-3824
Legal status
Legal status
  • Rx in China
Identifiers
IUPAC name
  • (1R,2S,3S,4R,5R)-5-[4-Chloro-3-[(4-ethoxy-3-fluorophenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC22H24ClFO7
Molar mass454.88 g·mol−1

Henagliflozin is a pharmaceutical drug for the treatment of type 2 diabetes.[1] In China, it is approved for adult patients with type 2 diabetes to improve the glycemic control.[2][3]

Henagliflozin, like other drugs of the gliflozin class, inhibits the transporter protein sodium/glucose cotransporter 2 (SGLT2) which leads to a reduction in blood glucose levels.[4]

References

  1. ↑ Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, et al. (August 2021). "Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial". Diabetes, Obesity & Metabolism. 23 (8): 1754–1764. doi:10.1111/dom.14389. PMID 33769656.
  2. ↑ Wang G (17 February 2022). "Monthly Report: New Drug Approvals in China, January 2022". BaiPharm. Henagliflozin Proline Tablets
  3. ↑ "Henagliflozin - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG.
  4. ↑ He X, Liu G, Chen X, Wang Y, Liu R, Wang C, et al. (July 2023). "Pharmacokinetic and Pharmacodynamic Interactions Between Henagliflozin, a Novel Selective SGLT-2 Inhibitor, and Warfarin in Healthy Chinese Subjects". Clinical Therapeutics. 45 (7): 655–661. doi:10.1016/j.clinthera.2023.06.002. PMID 37451912.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.